Efficacy of small‑dose ganciclovir on cytomegalovirus infections in children and its effects on liver function and miR‑UL112‑3p expression

Wang,Qingxiu; Zhou,Wenzeng; Wang,Bin; Qin,Guoyun; Liu,Feng'ai; Liu,Dexiang; Han,Tengteng

doi:10.3892/etm.2021.10344

Efficacy of small‑dose ganciclovir on cytomegalovirus infections in children and its effects on liver function and miR‑UL112‑3p expression

Authors:
- Qingxiu Wang
- Wenzeng Zhou
- Bin Wang
- Guoyun Qin
- Feng'ai Liu
- Dexiang Liu
- Tengteng Han
View Affiliations

Affiliations: Office of Hospital Infection Management, Affiliated Hospital of Weifang Medical University, Weifang, Shandong 261031, P.R. China, Department of Child Rehabilitation, Zaozhuang Maternal and Child Health Hospital of Shandong Province, Zaozhuang, Shandong 277100, P.R. China, Department of Child Rehabilitation, The Second People's Hospital of Liaocheng, Liaocheng, Shandong 252600, P.R. China, Department of Pharmacy, Yidu Central Hospital, Weifang, Shandong 262500, P.R. China, Department of Paediatrics, Haiyang People's Hospital of Shandong Province, Haiyang, Shandong 265100, P.R. China, Department of Pediatrics, Laoling People's Hospital, Laoling, Shandong 253600, P.R. China
Published online on: June 29, 2021 https://doi.org/10.3892/etm.2021.10344
Article Number: 912

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the study was to explore the efficacy of small‑dose ganciclovir on cytomegalovirus infections as well as its effects on the liver function and miR‑UL112‑3p of children. A total of 141 children infected with cytomegalovirus admitted to the Affiliated Hospital of Weifang Medical University from May 2015 to August 2017 were enrolled, of which 74 children were treated with small‑dose ganciclovir as an observation group (Obs group), and the rest were treated with conventional‑dose ganciclovir as a control group (Con group). The two groups were compared in efficacy after treatment, changes of liver function indexes [total bilirubin (TB), alanine aminotransferase (ALT), and aspartate aminotransferase (AST)] and miR‑UL112‑3p before and after treatment, and adverse reactions after treatment. A receiver operating characteristic (ROC) curve was drawn to analyze the value of miR‑UL112‑3p in predicating efficacy on cytomegalovirus infections in children, and Pearson's correlation analysis was carried out to analyze the correlation between miR‑UL112‑3p expression and TB, ALT and AST. The MV‑DNA level between the two groups after treatment was compared. The two groups showed no significant difference in efficacy and adverse reactions (both P>0.05), and before treatment, there was also no significant difference between the two groups in miR‑UL112‑3p, TB, ALT, and AST, while after treatment, both groups showed lower levels of miR‑UL112‑3p, TB, ALT, and AST, and the Obs group showed significantly lower levels thereof than the Con group (all P<0.05). In addition, the area under the curve (AUC), specificity, and sensitivity of miR‑UL112‑3p in the ROC curve of the Obs group were 0.866, 73.77 and 84.62%, respectively, while the AUC, specificity, and sensitivity of the ROC of the Con group were 0.837, 75.44, and 90.00%, respectively. Furthermore, miR‑UL112‑3p was positively correlated with TB, ALT, and AST, respectively. The CMV‑DNA level in the Obs group was lower than that in the Con group, but the difference was not significant, and the level of CMV‑DNA was positively correlated with that of miR‑UL112‑3p. In conclusion, small‑dose ganciclovir can better improve the liver function of the children, and downregulate miR‑UL112‑3p in them. The AUC, specificity, and sensitivity of miR‑UL112‑3p for predicting the efficacy of small‑dose ganciclovir were 0.866, 73.77 and 84.62%, respectively, and the AUC, specificity, and sensitivityfor predicting the efficacy of conventional‑dose ganciclovir were 0.837, 75.44 and 90.00%, respectively.

View Figures

View References

1	Sun H, Li S, Yan Y, Chen Z, Wang Y, Hao C and Ji W: Associations between patient clinical characteristics and the presence of cytomegalovirus DNA in the bronchoalveolar lavage fluid of children with recurrent wheezing. BMC Infect Dis. 18(458)2018.PubMed/NCBI View Article : Google Scholar
2	Neant N, Klifa R, Bouazza N, Moshous D, Neven B, Leruez-Ville M, Blanche S, Treluyer JM, Hirt D and Frange P: Model of population pharmacokinetics of cidofovir in immunocompromised children with cytomegalovirus and adenovirus infection. J Antimicrob Chemother. 73:2422–2429. 2018.PubMed/NCBI View Article : Google Scholar
3	Gentile I, Zappulo E, Riccio MP, Binda S, Bubba L, Pellegrinelli L, Scognamiglio D, Operto F, Margari L, Borgia G and Bravaccio C: Prevalence of congenital cytomegalovirus infection assessed through viral genome detection in dried blood spots in children with autism spectrum disorders. In Vivo. 31:467–473. 2017.PubMed/NCBI View Article : Google Scholar
4	Riga M, Korres G, Chouridis P, Naxakis S and Danielides V: Congenital cytomegalovirus infection inducing non-congenital sensorineural hearing loss during childhood; a systematic review. Int J Pediatr Otorhinolaryngol. 115:156–164. 2018.PubMed/NCBI View Article : Google Scholar
5	Palma S, Roversi MF, Bettini M, Mazzoni S, Pietrosemoli P, Lucaccioni L, Berardi A and Genovese E: Hearing loss in children with congenital cytomegalovirus infection: An 11-year retrospective study based on laboratory database of a tertiary paediatric hospital. Acta Otorhinolaryngol Ital. 39:40–45. 2019.PubMed/NCBI View Article : Google Scholar
6	Ghorbani S, Mahdavi R, Alipoor B, Panahi G, Nasli Esfahani E, Razi F, Taghikhani M and Meshkani R: Decreased serum microRNA-21 level is associated with obesity in healthy and type 2 diabetic subjects. Arch Physiol Biochem. 124:300–305. 2018.PubMed/NCBI View Article : Google Scholar
7	Gong YY, Luo JY, Wang L and Huang Y: MicroRNAs regulating reactive oxygen species in cardiovascular diseases. Antioxid Redox Signal. 29:1092–1107. 2018.PubMed/NCBI View Article : Google Scholar
8	Belarbi Y, Mejhert N, Gao H, Arner P, Rydén M and Kulyté A: MicroRNAs-361-5p and miR-574-5p associate with human adipose morphology and regulate EBF1 expression in white adipose tissue. Mol Cell Endocrinol. 472:50–56. 2018.PubMed/NCBI View Article : Google Scholar
9	Ding M, Wang X, Wang C, Liu X, Zen K, Wang W, Zhang CY and Zhang C: Distinct expression profile of HCMV encoded miRNAs in plasma from oral lichen planus patients. J Transl Med. 15(133)2017.PubMed/NCBI View Article : Google Scholar
10	Liang Q, Wang K, Wang B and Cai Q: HCMV-encoded miR-UL112-3p promotes glioblastoma progression via tumour suppressor candidate 3. Sci Rep. 7(44705)2017.PubMed/NCBI View Article : Google Scholar
11	Pan Y, Wang N, Zhou Z, Liang H, Pan C, Zhu D, Liu F, Zhang CY, Zhang Y and Zen K: Circulating human cytomegalovirus-encoded HCMV-miR-US4-1 as an indicator for predicting the efficacy of IFNα treatment in chronic hepatitis B patients. Sci Rep. 6(23007)2016.PubMed/NCBI View Article : Google Scholar
12	Mukhopadhyay R, Roy S, Venkatadri R, Su YP, Ye W, Barnaeva E, Mathews Griner L, Southall N, Hu X, Wang AQ, et al: Efficacy and mechanism of action of low dose emetine against human cytomegalovirus. PLoS Pathog. 12(e1005717)2016.PubMed/NCBI View Article : Google Scholar
13	Aryal S, Katugaha SB, Cochrane A, Brown AW, Nathan SD, Shlobin OA, Ahmad K, Marinak L, Chun J, Fregoso M, et al: Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients. Transpl Infect Dis. 21(e13166)2019.PubMed/NCBI View Article : Google Scholar
14	Li J, Pan CW, Zhou GY, Zhuge L, Fang PP, Jin LX, Lin W, Lin XZ and Zheng Y: Studies on the interference of ganciclovir to HCV liver fibrosis. Eur Rev Med Pharmacol Sci. 20:4343–4347. 2016.PubMed/NCBI
15	Kuwahara-Ota S, Chinen Y, Mizuno Y, Takimoto-Shimomura T, Matsumura-Kimoto Y, Tanba K, Tsukamoto T, Mizutani S, Shimura Y, Kobayashi T, et al: Human herpesvirus-6 pneumonitis in a patient with follicular lymphoma following immunochemotherapy with rituximab. Infect Drug Resist. 11:701–705. 2018.PubMed/NCBI View Article : Google Scholar
16	Ju HY, Kang HJ, Hong CR, Lee JW, Kim H, Park KD, Shin HY, Park JD, Choi EH, Lee HJ and Ahn HS: Half-dose ganciclovir preemptive treatment of cytomegalovirus infection after pediatric allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 18:396–404. 2016.PubMed/NCBI View Article : Google Scholar
17	Liu LW, Qian JH, Zhu TW, Zhang YH and Zhu JX: A 5-year retrospective clinical study of perinatal cytomegalovirus infection. Zhongguo Dang Dai Er Ke Za Zhi. 18:99–104. 2016.PubMed/NCBI View Article : Google Scholar : (In Chinese).
18	Yin CM, Suen WC, Lin S, Wu XM, Li G and Pan XH: Dysregulation of both miR-140-3p and miR-140-5p in synovial fluid correlate with osteoarthritis severity. Bone Joint Res. 6:612–618. 2017.PubMed/NCBI View Article : Google Scholar
19	Kasmapour B, Kubsch T, Rand U, Eiz-Vesper B, Messerle M, Vondran FWR, Wiegmann B, Haverich A and Cicin-Sain L: Myeloid dendritic cells repress human cytomegalovirus gene expression and spread by releasing interferon-unrelated soluble antiviral factors. J Virol. 92:e01138–17. 2017.PubMed/NCBI View Article : Google Scholar
20	Piret J and Boivin G: Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance. Antiviral Res. 163:91–105. 2019.PubMed/NCBI View Article : Google Scholar
21	Ye B and Zhao H: Early abnormal liver enzyme levels may increase the prevalence of human cytomegalovirus antigenaemia after hematopoietic stem cell transplantation. J Int Med Res. 45:673–679. 2017.PubMed/NCBI View Article : Google Scholar
22	Nolan N, Halai UA, Regunath H, Smith L, Rojas-Moreno C and Salzer W: Primary cytomegalovirus infection in immunocompetent adults in the United States-A case series. IDCases. 10:123–126. 2017.PubMed/NCBI View Article : Google Scholar
23	Ando G, Taguchi K, Enoki Y, Yokoyama Y, Kizu J and Matsumoto K: Evaluation of the expression time of ganciclovir-induced adverse events using JADER and FAERS. Biol Pharm Bull. 42:1799–1804. 2019.PubMed/NCBI View Article : Google Scholar
24	Imai S, Yamada T, Kasashi K, Ishiguro N, Kobayashi M and Iseki K: Construction of a flow chart-like risk prediction model of ganciclovir-induced neutropaenia including severity grade: A data mining approach using decision tree. J Clin Pharm Ther. 44:726–734. 2019.PubMed/NCBI View Article : Google Scholar
25	Zhang J, Huang Y, Wang Q, Ma Y, Qi Y, Liu Z, Deng J and Ruan Q: Levels of human cytomegalovirus miR-US25-1-5p and miR-UL112-3p in serum extracellular vesicles from infants with HCMV active infection are significantly correlated with liver damage. Eur J Clin Microbiol Infect Dis. 39:471–481. 2020.PubMed/NCBI View Article : Google Scholar
26	Landais I, Pelton C, Streblow D, DeFilippis V, McWeeney S and Nelson JA: Human cytomegalovirus miR-UL112-3p targets TLR2 and modulates the TLR2/IRAK1/NFκB signaling pathway. PLoS Pathog. 11(e1004881)2015.PubMed/NCBI View Article : Google Scholar
27	Britt WJ and Prichard MN: New therapies for human cytomegalovirus infections. Antiviral Res. 159:153–174. 2018.PubMed/NCBI View Article : Google Scholar
28	Hahn F, Hutterer C, Henry C, Hamilton ST, Strojan H, Kraut A, Schulte U, Schütz M, Kohrt S, Wangen C, et al: Novel cytomegalovirus-inhibitory compounds of the class pyrrolopyridines show a complex pattern of target binding that suggests an unusual mechanism of antiviral activity. Antiviral Res. 159:84–94. 2018.PubMed/NCBI View Article : Google Scholar
29	Andronova VL: Modern ethiotropic chemotherapy of human cytomegalovirus infection: Clinical effectiveness, molecular mechanism of action, drug resistance, new trends and prospects. Part 1. Vopr Virusol. 63:202–211. 2018.PubMed/NCBI View Article : Google Scholar : (In Russian).